Drug Research

The pharmaceutical industry is currently witnessing a transformative shift from a mass-production model to a patient-centric approach, driven largely by the innovation of 3D printed dosage forms advancing precision medicine. For over a century, the standard of care has...

The pharmaceutical industry is currently undergoing a data-driven revolution that is fundamentally changing how medications are designed and optimized. For decades, drug development was a linear process that culminated in randomized controlled trials (RCTs). While RCTs are essential for...

Bayer has strengthened its pharmaceutical and ophthalmology portfolio through two separate transactions, completing the acquisition of Perfuse Therapeutics while also entering a collaboration agreement with Iambic Therapeutics. The moves provide Bayer with full ownership of Perfuse’s lead asset, PER-001,...

The US Department of Health and Human Services (HHS) has outlined a new strategy aimed at reinforcing the country’s position in pharmaceutical research as competition from China intensifies. Through an initiative called Operation Trailblazer, HHS plans to introduce measures...

Johnson & Johnson (J&J) has entered into a definitive agreement to acquire Firefly Bio for $1bn in cash, a move aimed at expanding its oncology research portfolio through the addition of Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) technology....

Sanofi has entered into a multi-year agreement with France-based agentic AI company Owkin to jointly develop next-generation AI-driven biopharma agents. The partnership includes a five-year licence for Owkin's K Pro platform, an advanced AI system designed to augment drug...

The Pfizer Innovent Cancer Deal has been finalized, establishing a global licensing and collaboration agreement valued at up to $10.5 billion. The transaction focuses on the research, development, and commercialization of 12 early-stage oncology programs. This arrangement combines the...